Company Filing History:
Years Active: 2023-2025
Title: Innovations of Junxia Wei in Immunotoxin Development
Introduction
Junxia Wei is a prominent inventor based in Rockville, MD, who has made significant contributions to the field of immunotoxins. With a total of two patents to his name, Wei's work focuses on developing novel therapeutic molecules aimed at treating cancer. His innovative approach combines various biological components to enhance the efficacy of cancer treatments.
Latest Patents
Wei's latest patents revolve around the creation of immunotoxins with an albumin binding domain. These molecules consist of multiple domains, including a targeting moiety, an albumin binding domain (ABD), a furin cleavage sequence (FCS), and an optionally substituted Domain III from exotoxin A (PE). The patents also disclose related nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions. Furthermore, they outline methods for producing these molecules and their applications in treating or preventing cancer in mammals, as well as inhibiting the growth of target cells.
Career Highlights
Junxia Wei is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research in the field of immunology and cancer treatment. Wei's contributions have been instrumental in advancing the understanding and application of immunotoxins in medical science.
Collaborations
Wei has collaborated with notable colleagues, including Ira H. Pastan and Masanori Onda. These partnerships have fostered a collaborative environment that enhances the research and development of innovative cancer therapies.
Conclusion
Junxia Wei's work in the development of immunotoxins represents a significant advancement in cancer treatment. His innovative patents and collaborations with esteemed colleagues highlight his commitment to improving therapeutic options for patients.